U.S. markets close in 3 hours 12 minutes
  • S&P 500

    4,236.38
    -10.21 (-0.24%)
     
  • Dow 30

    34,198.09
    -101.24 (-0.30%)
     
  • Nasdaq

    14,048.96
    -23.89 (-0.17%)
     
  • Russell 2000

    2,309.04
    -11.03 (-0.48%)
     
  • Crude Oil

    72.34
    +0.22 (+0.31%)
     
  • Gold

    1,861.20
    +4.80 (+0.26%)
     
  • Silver

    27.82
    +0.13 (+0.46%)
     
  • EUR/USD

    1.2118
    -0.0015 (-0.12%)
     
  • 10-Yr Bond

    1.4870
    -0.0120 (-0.80%)
     
  • GBP/USD

    1.4101
    +0.0018 (+0.13%)
     
  • USD/JPY

    109.9000
    -0.1340 (-0.12%)
     
  • BTC-USD

    38,773.98
    -1,364.39 (-3.40%)
     
  • CMC Crypto 200

    959.66
    -32.81 (-3.31%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Here's What Investors Need to Know About the Sputnik V Coronavirus Vaccine

·4 min read
Here's What Investors Need to Know About the Sputnik V Coronavirus Vaccine
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

When someone comments on "the Sputnik" these days, you can bet your hat that they're not talking about the first satellite to reach low Earth orbit -- they're talking about the Russian coronavirus vaccine candidate. While the present-day Sputnik vaccine didn't take first place in its own race as its satellite predecessor did, it's still worth knowing about, because it changes the global competitive landscape for COVID vaccines. According to phase 3 clinical trial results published last Tuesday in the prestigious medical journal The Lancet, the Sputnik V vaccine is around 91% effective at preventing severe disease.